PTC cuts gene therapy programs, discloses PhIII fail in Friedreich's ataxia and CFO exit
PTC Therapeutics disclosed a string of disappointing news late Tuesday, revealing a Phase III flop, a pipeline reorg to cut gene therapy programs and its CFO’s sudden departure.
The dramatic shakeup — which will lead to layoffs of an unknown number of employees — comes just two months after Matthew Klein took over as CEO from longtime leader Stuart Peltz. Shares of the biotech $PTCT sank 21% to $46 in pre-market trading Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.